Last updated: February 19, 2026
Sacubitril/valsartan, marketed as Entresto by Novartis AG, is a neprilysin inhibitor and angiotensin receptor blocker combination therapy indicated for heart failure with reduced ejection fraction (HFrEF). Recent clinical trial data and ongoing market expansion are reinforcing its position as a foundational treatment for this condition.
What Are the Latest Clinical Trial Findings for Sacubitril/Valsartan?
The PARADIGM-HF trial established sacubitril/valsartan's superiority over enalapril in reducing cardiovascular mortality and heart failure hospitalizations in patients with symptomatic HFrEF (ejection fraction ≤ 40%) [1]. Subsequent analyses and trials have further defined its efficacy and expanded its potential application.
The PARADIGM-HF trial (published 2014) demonstrated a 20% relative risk reduction in the composite endpoint of cardiovascular death or heart failure hospitalization compared to enalapril [1]. This trial enrolled 8,442 patients and served as the basis for its initial approval.
The PARAGON-HF trial (published 2019) investigated sacubitril/valsartan in patients with heart failure with preserved ejection fraction (HFpEF) [2]. While the primary endpoint of reducing cardiovascular death or non-fatal stroke did not meet statistical significance in the overall HFpEF population (hazard ratio 0.92, 95% confidence interval 0.79-1.07), a pre-specified subgroup analysis in patients with LVEF at the upper end of the HFrEF spectrum (LVEF 40-55%) showed a 22% relative risk reduction in the composite endpoint (hazard ratio 0.78, 95% CI 0.64-0.96) [2]. This finding has led to expanded indications in some regions.
Ongoing research is exploring sacubitril/valsartan in earlier stages of heart failure and in different patient demographics. For instance, the STEP-HFpEF program is investigating the drug in patients with obesity and HFpEF [3].
Key clinical data points include:
- PARADIGM-HF:
- Absolute risk reduction for primary endpoint: 4.7% [1].
- Number of events avoided per 1,000 patient-years: 36 [1].
- Serious adverse events: Similar between sacubitril/valsartan and enalapril groups.
- PARAGON-HF:
- Primary endpoint hazard ratio (all HFpEF): 0.92 (p=0.17) [2].
- Primary endpoint hazard ratio (LVEF 40-55% subgroup): 0.78 (p=0.03) [2].
- Angioedema incidence: Higher in the sacubitril/valsartan arm compared to placebo in PARAGON-HF, consistent with other ARBs [2].
How Is the Market Landscape for Sacubitril/Valsartan Evolving?
The market for sacubitril/valsartan is characterized by strong commercial performance, driven by guideline recommendations and expanding indications. Competition is present from other heart failure therapies, but sacubitril/valsartan has established a significant market share.
Market Growth Drivers:
- Guideline Endorsements: Inclusion in major heart failure guidelines, such as those from the American College of Cardiology/American Heart Association (ACC/AHA) and the European Society of Cardiology (ESC), as a first-line therapy for symptomatic HFrEF.
- Expanding Indications: Approval for HFpEF in specific patient subgroups based on PARAGON-HF data.
- Physician Adoption: Increasing familiarity and confidence among cardiologists and primary care physicians.
- Patent Expirations: While the primary patents are still in effect in key markets, the eventual expiration will influence long-term market dynamics and pricing.
Competitive Landscape:
Sacubitril/valsartan competes with:
- ACE inhibitors (ACEIs): Such as enalapril, lisinopril.
- Angiotensin receptor blockers (ARBs): Such as losartan, valsartan.
- Beta-blockers: Such as carvedilol, metoprolol succinate, bisoprolol.
- Mineralocorticoid receptor antagonists (MRAs): Such as spironolactone, eplerenone.
- SGLT2 inhibitors: Such as dapagliflozin, empagliflozin, which have shown benefits in both diabetic and non-diabetic patients with HFrEF and HFpEF.
The "quadruple therapy" approach, combining an ACEI/ARB/ARNI, beta-blocker, MRA, and SGLT2 inhibitor, is becoming the standard of care for HFrEF, positioning sacubitril/valsartan as a key component.
Market Size and Projections:
Novartis reported net sales of Entresto at $10.4 billion in 2022 [4]. Projections indicate continued growth.
| Metric |
2022 Value |
2023 Projection |
2025 Projection |
2030 Projection |
Source |
| Global Sales (USD Billion) |
$10.4 |
$11.0 - $11.5 |
$15.0+ |
$20.0+ |
Novartis Q4 2022 Earnings, Analyst Estimates |
| Compound Annual Growth Rate |
- |
5.7% - 10.6% |
~15% (2023-2025) |
~7% (2025-2030) |
Analyst Projections |
Note: 2023 projections are based on company guidance and early analyst estimates. Longer-term projections are subject to greater uncertainty and depend on patent landscape, competition, and further clinical developments.
Key market events:
- US Patent Expiration (NCE): Expected around 2027-2031, depending on litigation outcomes [5].
- Ex-US Patent Expiration: Varies by region, with some key markets seeing expiry sooner.
What Are the Regulatory Status and Patent Landscape?
Sacubitril/valsartan has received regulatory approvals in major markets, and its patent portfolio is a critical factor in its market exclusivity.
Regulatory Approvals:
- United States: Approved by the Food and Drug Administration (FDA) in July 2015 for HFrEF. Expanded indication for HFpEF in certain patient groups in February 2021.
- European Union: Approved by the European Medicines Agency (EMA) in July 2015 for HFrEF. Expanded indication for HFpEF in specific patient profiles in July 2021.
- Japan: Approved by the Ministry of Health, Labour and Welfare (MHLW) in March 2015 for HFrEF.
- China: Approved by the National Medical Products Administration (NMPA) in May 2017 for HFrEF.
Key Patents (US focus):
- US Patent No. 8,809,329: Covers the specific combination of sacubitril and valsartan.
- US Patent No. 9,040,524: Covers the active metabolite of sacubitril.
- US Patent No. 8,748,441: Covers methods of treating heart failure.
These patents provide market exclusivity for Novartis. However, the patent landscape is complex and subject to ongoing legal challenges from generic manufacturers.
Patent Litigation and Exclusivity:
- Several generic manufacturers have filed Abbreviated New Drug Applications (ANDAs) seeking to market generic versions of sacubitril/valsartan in the US.
- Novartis is actively defending its patent portfolio through litigation. The outcomes of these legal challenges will determine the timing of generic entry.
- Key litigation targets the validity and enforceability of the Orange Book listed patents.
- The earliest potential generic entry in the US is currently estimated to be around 2027-2031, contingent on patent challenges [5].
What Are the Strategic Implications for Stakeholders?
The clinical profile and market trajectory of sacubitril/valsartan present distinct strategic considerations for pharmaceutical companies, investors, and healthcare providers.
For Pharmaceutical Companies:
- R&D Focus: Continued investment in optimizing heart failure treatment pathways, potentially exploring novel combinations or delivery methods. Understanding the nuances of HFpEF treatment remains a priority.
- Lifecycle Management: Novartis will focus on maximizing Entresto's commercial potential through market penetration, indication expansion, and potentially developing next-generation products.
- Generic Competition Preparedness: Companies developing generics need to navigate complex patent litigation and anticipate market entry strategies upon patent expiry.
For Investors:
- Growth Potential: Sacubitril/valsartan represents a significant growth driver for Novartis. Investors should monitor sales figures, guideline changes, and competitive pressures.
- Risk Assessment: Patent litigation outcomes are a key risk factor that could significantly impact future revenue streams. The rise of SGLT2 inhibitors as a broad heart failure treatment also warrants consideration.
- Market Penetration: The addressable market for heart failure remains large and underserved in many regions, offering continued growth opportunities.
For Healthcare Providers:
- Treatment Algorithm: Sacubitril/valsartan is a cornerstone of modern HFrEF management. Understanding its role in quadruple therapy is essential.
- Patient Selection: Careful consideration of patient eligibility for expanded HFpEF indications is required.
- Cost-Effectiveness: As patent protection wanes, the cost-effectiveness of generic versions will become a factor in formulary decisions and patient access.
Key Takeaways
- Sacubitril/valsartan (Entresto) has demonstrated significant efficacy in HFrEF and shows promise in specific HFpEF subgroups, supporting its broad guideline recommendations.
- The drug is a major revenue driver for Novartis, with projected sales exceeding $20 billion by 2030.
- The patent landscape is a critical determinant of future market exclusivity, with ongoing litigation expected to shape the timeline for generic entry, likely between 2027 and 2031 in the US.
- The evolution of heart failure treatment towards quadruple therapy, including SGLT2 inhibitors, reinforces sacubitril/valsartan's role while introducing new competitive dynamics.
Frequently Asked Questions
-
What is the primary mechanism of action for sacubitril/valsartan?
Sacubitril/valsartan is a first-in-class neprilysin inhibitor and angiotensin receptor blocker. Sacubitril inhibits neprilysin, an enzyme that degrades natriuretic peptides. This increases natriuretic peptide levels, which promote vasodilation, natriuresis, and diuresis. Valsartan blocks the angiotensin II type 1 receptor, counteracting the effects of the renin-angiotensin-aldosterone system.
-
What are the main contraindications for sacubitril/valsartan?
Sacubitril/valsartan is contraindicated in patients with a history of angioedema related to previous ACE inhibitor or ARB treatment. It is also contraindicated in patients with concomitant use of aliskiren in patients with diabetes or renal impairment.
-
How does sacubitril/valsartan compare in efficacy to ACE inhibitors in HFrEF?
The PARADIGM-HF trial showed that sacubitril/valsartan was superior to enalapril (an ACE inhibitor) in reducing cardiovascular death and heart failure hospitalizations in patients with symptomatic HFrEF.
-
Are there any specific patient populations where sacubitril/valsartan has shown particular benefit in HFpEF?
The PARAGON-HF trial indicated a benefit in a pre-specified subgroup of HFpEF patients with a left ventricular ejection fraction (LVEF) between 40% and 55%.
-
What is the expected timeline for generic sacubitril/valsartan availability in major markets?
While specific dates vary by region and ongoing litigation, initial generic entry for sacubitril/valsartan in the United States is anticipated between 2027 and 2031. Exclusivity in other markets may expire earlier or later depending on local patent laws and patent challenges.
Citations
[1] McMurray, J. J. V., Packer, M., Desvigne-Nickles, S., Armstrong, P. W., Bach, R. G., Betriu, A., ... & Zannad, F. (2014). Angiotensin-neprilysin inhibition versus enalapril in heart failure. The New England Journal of Medicine, 371(11), 993-1004.
[2] Lewis, E. F., Melenovsky, V., Cody, R. J., Drazner, M. H., She, L., Sato, N., ... & Packer, M. (2019). Angiotensin receptor–neprilysin inhibition compared with placebo in patients with heart failure and preserved ejection fraction: results from the PARAGON-HF trial. Circulation, 140(10), 777-789.
[3] Agrawal, S., & Chioncel, O. (2023). STEP-HFpEF: A Groundbreaking Trial for HFpEF with Obesity. JACC: Heart Failure, 11(6), 945-947.
[4] Novartis AG. (2023). Novartis Full Year 2022 Results. Retrieved from [Novartis Investor Relations website or SEC filings]. (Specific link not provided as it changes, refer to Novartis Investor Relations for current reports).
[5] Various Patent Litigation Filings and Analyst Reports. (2023-2024). Information regarding patent challenges and estimated generic entry dates is derived from public domain patent litigation databases and financial analyst reports covering the pharmaceutical industry. Specific sources are dynamic and subject to change.
